Non-interventional Study of Effectiveness of Elderly Metastatic Renal Cell Carcinoma (mRCC) Treated With Sorafenib
N/A
65 Years
N/A
65 Years
N/A
Open (Enrolling)
Both
Carcinoma, Renal Cell
Both
Carcinoma, Renal Cell
Trial Information
Non-interventional Study of Effectiveness of Elderly Metastatic Renal Cell Carcinoma (mRCC) Treated With Sorafenib
Inclusion Criteria:
- Patients with histologically/cytologically diagnosed metastasis RCC who are
candidates for systemic therapy and have decided to accept Sorafenib treatment.
- >=65 years of age
- Patients who have signed the informed consent
- Patients with a life expectancy of ≥12 weeks
- No prior systemic treatment
Exclusion Criteria:
- The approved local product lable must be followed for the exclusion criteria
Type of Study:
Observational
Study Design:
Observational Model: Cohort, Time Perspective: Prospective
Outcome Measure:
overall survival
Outcome Time Frame:
up to 2.5 years
Safety Issue:
No
Principal Investigator
Bayer Study Director
Investigator Role:
Study Director
Investigator Affiliation:
Bayer
Authority:
China: Food and Drug Administration
Study ID:
16399
NCT ID:
NCT01728948
Start Date:
December 2012
Completion Date:
September 2016
Related Keywords:
- Carcinoma, Renal Cell
- Sorafenib
- renal cell carcinoma(RCC)
- elderly
- effectiveness
- safety
- Carcinoma
- Carcinoma, Renal Cell
Name | Location |
|---|
